×

Geron discontinues late-stage trial of blood cancer drug, shares plunge

By Thomson Reuters Oct 28, 2026 | 7:15 AM

By Christy Santhosh

Oct 28 (Reuters) – Geron said on Wednesday it would halt a late-stage trial of its blood cancer treatment, marking a setback for ​the company’s only commercial product, sending its shares ‌plunging 20% in early trading.

The drug, branded as Rytelo, was being evaluated as a treatment for myelofibrosis, a rare type of blood cancer in which scar tissue gradually builds up in the ‌bone ​marrow.

Geron said it made the decision ⁠following an independent data ⁠monitoring committee’s recommendation that the trial, named IMpactMF, was unlikely to achieve its main goal of overall survival, compared with the best available therapy.

Rytelo received US approval ​in 2024 for treating transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS), a group of blood cancers.

The ⁠trial was disappointing, but no ⁠new safety concerns were seen despite higher ​and more frequent dosing than in LR-MDS, supporting confidence in ​the ongoing Rytelo launch, said TD Cowen analyst Tara ‌Bancroft.

Geron said a detailed analysis of the data would be conducted, and study findings would be shared at a future date.

The trial enrolled 327 patients with high-risk ⁠myelofibrosis whose disease had returned or failed to respond after treatment with a JAK inhibitor, a type of drug used to ⁠manage symptoms ‌and reduce spleen enlargement.

“We do not believe ⁠this outcome meaningfully alters physician perception of ​Rytelo ‌in LR-MDS as the compound’s approved indication ​and the ⁠anchor of the commercial story,” said Wedbush analyst Robert Driscoll.

Rytelo competes with Bristol Myers Squibb’s Reblozyl. It generated $57.5 million in second-quarter revenue, and the company expects full-year sales of $220 million to $240 million.

(Reporting by Christy Santhosh in Bengaluru; Editing ​by Maju Samuel)